Business Context and Reporting Period
This Form 8-K was filed by 180 Life Sciences Corp. (formerly KBL Merger Corp. IV) on November 9, 2020. The filing announces the consummation of a Business Combination Agreement originally dated July 25, 2019. The transaction involves the merger of KBL Merger Sub, Inc. with 180 Life Sciences Corp. and its subsidiaries (Katexco Pharmaceuticals Corp., CannBioRex Pharmaceuticals Corp., and 180 Therapeutics L.P.).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate event rather than a financial performance statement.
Material Changes
- Corporate Structure: The business combination has been completed, resulting in the merger of the operating entities into the public shell company.
- Corporate Name: The registrant's name has changed from KBL Merger Corp. IV to 180 Life Sciences Corp.
- Securities: The company lists Common Stock (Trading Symbol: ATNF) and Warrants (Trading Symbol: ATNFW) on The NASDAQ Stock Market LLC.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors. It explicitly states that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination of materiality under Regulation FD.
Investor Verification Checklist
- Verify the terms of the Business Combination Agreement and the pro forma capital structure in the attached press release (Exhibit 99.1).
- Confirm the trading status and ticker symbols (ATNF, ATNFW) on NASDAQ following the merger.
- Review the press release for details on the consideration paid to shareholders of the 180 Parties.
- Check subsequent filings for the first audited financial statements of the combined entity.